electroCore, Inc. (ECOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ECOR Stock Summary
- ELECTROCORE INC's market capitalization of $17,333,655 is ahead of just 7.27% of US-listed equities.
- The ratio of debt to operating expenses for ELECTROCORE INC is higher than it is for about only 7.23% of US stocks.
- In terms of volatility of its share price, ECOR is more volatile than 99.47% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ELECTROCORE INC, a group of peers worth examining would be PLAB, SNES, AXGN, REFR, and ATRC.
- Visit ECOR's SEC page to see the company's official filings. To visit the company's web site, go to www.electrocore.com.
ECOR Valuation Summary
- In comparison to the median Healthcare stock, ECOR's EV/EBIT ratio is 98.47% lower, now standing at 0.1.
- ECOR's price/earnings ratio has moved up 14.6 over the prior 58 months.
Below are key valuation metrics over time for ECOR.
ECOR's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- ECOR has a Quality Grade of D, ranking ahead of 7.18% of graded US stocks.
- ECOR's asset turnover comes in at 0.134 -- ranking 150th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows ECOR's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
ECOR Price Target
For more insight on analysts targets of ECOR, see our ECOR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
|Average Price Target||$3.60||Average Broker Recommendation||1.5 (Moderate Buy)|
ECOR Stock Price Chart Interactive Chart >
ECOR Price/Volume Stats
|Current price||$5.34||52-week high||$10.50|
|Prev. close||$4.28||52-week low||$2.92|
|Day high||$5.65||Avg. volume||25,177|
|50-day MA||$4.44||Dividend yield||N/A|
|200-day MA||$6.04||Market Cap||25.32M|
electroCore, Inc. (ECOR) Company Bio
electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is based in Basking Ridge, New Jersey.
Most Popular Stories View All
ECOR Latest News Stream
|Loading, please wait...|
ECOR Latest Social Stream
View Full ECOR Social Stream
Latest ECOR News From Around the Web
Below are the latest news stories about ELECTROCORE INC that investors may wish to consider to help them evaluate ECOR as an investment opportunity.
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper entitled “Non-Invasive Vagus Nerve Stimulation Improves Brain Lesion Volume and Neurobehavioral Outcomes in a Rat Model of Traumatic Brain Injury” in the peer-re
electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a TruvagaTM focus group study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, the Truvaga product helped its users improve stress, anxiety, sleep, energy, and mood.In the in-home focus group study, 34 participants were instructed to use the T
electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
ROCKAWAY, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank. electroCore does not hold cash deposits or securities with these banking institutions, and currently holds corporate cash accounts with large global money center banks.About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectron
electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second LanguageROCKAWAY, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that data from a sham controlled study on the ability of nVNS to Accelerate Second Language Learning, conducted at the Defense Language Institute in Monterey, California, will be presented at the 2023 American Acade
electroCore, Inc. (NASDAQ:ECOR) Q4 2022 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Hello, and welcome to the electroCore Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast . As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Nicole Jones at CG Capital. Please go […]
ECOR Price Returns
Continue Researching ECORWant to do more research on electroCore Inc's stock and its price? Try the links below:
electroCore Inc (ECOR) Stock Price | Nasdaq
electroCore Inc (ECOR) Stock Quote, History and News - Yahoo Finance
electroCore Inc (ECOR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...